Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

Eitemau Tebyg

• Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
  gan: Liao, Bin-Chi, et al.
  Cyhoeddwyd: (2019)
• Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
  gan: O’Kane, G.M., et al.
  Cyhoeddwyd: (2018)
• The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
  gan: Huang, Yen-Hsiang, et al.
  Cyhoeddwyd: (2018)
• Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts
  gan: Hu, Peng, et al.
  Cyhoeddwyd: (2016)
• Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)?
  gan: Takabe, Kazuaki
  Cyhoeddwyd: (2011)